Safety monitoring and information
Understand the ways we work to ensure medicines and medical devices remain as safe and effective as possible. Access information on product safety topics.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
What safety means
Safety is determined by weighing the known and potential risks, against the expected benefits when a therapeutic good is used as intended. While some risks are identified during the approval process, others may only become apparent after broader use.
The safety of therapeutic goods is a shared responsibility between regulators, sponsors, healthcare professionals and consumers.
How we monitor safety
We monitor safety through a range of different activities:
- Pre-market evaluation: Products must meet strict safety, quality and efficacy standards before being included in the Australian Register of Therapeutic Goods (ARTG).
- Post-market surveillance: We monitor products once they are on the market through adverse event reports, product testing, recalls and safety reviews.
- Adverse event reporting: Anyone can report adverse events or side effects, product defects or safety concerns. These reports help identify emerging risks and inform regulatory action.
- Product testing and investigations: Our laboratories test therapeutic goods to ensure they meet Australian standards and compare results with international benchmarks. See further information on our Product testing and investigations.
- Recalls and market actions: If a safety issue is identified, we may initiate recalls, issue safety alerts or require product corrections.
A key activity in safety monitoring is identifying patterns that emerge when problems are reported by sponsors, health professionals and consumers. An adverse event occurring does not necessarily mean that there is something wrong with a therapeutic good. However, each report helps to build a picture of the safety profile of a product. You can Report an adverse event or safety problem.
Latest alerts
-
Kmart Australia Ltd is recalling their Anko Small Gel Pak and Anko Large Gel Pak because they contain ethylene glycol, a toxic substance.
-
Pharmaceutical companies Novo Nordisk and Eli Lilly are discontinuing some of their insulin products.
-
The company which has supplied the CellAED devices, RRR Manufacturing Pty Ltd, has gone into liquidation. The liquidators for RRR Manufacturing, are conducting a Critical Recall for all lots of the CellAED device.
Latest articles
-
Conviction for unlawful supply and advertising of black salve products
An individual has been sentenced for unlawfully advertising and supplying black salve and bloodroot capsules, and for advertising other unapproved therapeutic goods to treat serious conditions such as anxiety. -
Product Information safety updates - January 2026
Information for health professionals about medicines with safety related updates to their Product Information. -
Product Information safety updates - December 2025
Information for health professionals about medicines with safety related updates to their Product Information.
Latest publications
-
Communique from the 11th meeting of the Women's Health Products Working Group, 30 October 2025
-
Advisory Committee on Vaccines meeting statement 54
-
Medical device reforms: Consumer Working Group meeting statement, Meeting 17, 22 August 2025.
Open consultations
-
Survey on Digital Mental Health Tools
We are seeking input from stakeholders responsible for developing, deploying or supplying Digital Mental Health Tools (DMHT) to help us better understand these tools.